Moussa Sumer, Price Jordan, Frye Jesse, Chen On, Rahman Tahmid
Department of Medicine, Stony Brook University Hospital, Stony Brook, New York, USA.
Cardiology Division, Department of Medicine, Stony Brook University Hospital, Stony Brook, New York, USA.
JACC Case Rep. 2024 Dec 4;29(23):102716. doi: 10.1016/j.jaccas.2024.102716.
Primary hypoalphalipoproteinemia is typically caused by genetic disorders and is characterized by low high-density-lipoprotein cholesterol (HDL-C). Low HDL-C has been proposed to confer an increased risk of atherosclerotic cardiovascular disease; however, a causal relationship has not been determined. We describe the case of an otherwise healthy and asymptomatic 37-year-old woman with severely low HDL-C who was found to have significant coronary artery disease in whom genetic testing supported a diagnosis of Tangier disease. Current lipid management guidelines focus on optimization of total cholesterol and low-density-lipoprotein cholesterol (LDL-C), although the lipid profile of patients with primary hypoalphalipoproteinemia typically portrays favorable non-HDL levels. Clinical trials investigating medications that target low HDL-C have failed to show a clear benefit in cardiovascular outcomes. Based on current evidence, patients with genetic disorders that manifest through low HDL-C and optimal LDL-C should be managed with lifestyle modification and statin therapy.
原发性低高密度脂蛋白血症通常由遗传疾病引起,其特征是高密度脂蛋白胆固醇(HDL-C)水平低。有人提出,HDL-C水平低会增加动脉粥样硬化性心血管疾病的风险;然而,因果关系尚未确定。我们描述了一名37岁健康无症状女性的病例,她的HDL-C严重偏低,却被发现患有严重冠状动脉疾病,基因检测支持其诊断为丹吉尔病。目前的血脂管理指南侧重于优化总胆固醇和低密度脂蛋白胆固醇(LDL-C),尽管原发性低高密度脂蛋白血症患者的血脂谱通常显示非HDL水平良好。针对低HDL-C的药物进行的临床试验未能在心血管结局方面显示出明显益处。根据目前的证据,因HDL-C低和LDL-C正常而表现出遗传疾病的患者,应通过生活方式改变和他汀类药物治疗进行管理。